EGFR and lung carcinoma: Such an integrated approach of liquid biopsy and PGx testing could pave the way for precision therapy in lung cancer by tumor detection, dynamic monitoring of EGFR mutations and acquired resistance, as well as aid in the selection of precise drug therapy via serial molecular profiling from blood as shown in Fig. 1.